ArunaSubramanianMD

Infectious Disease • Stanford, CA

Physician

Join to view full profile

Dr. Subramanian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Subramanian's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Education & Training

Johns Hopkins UniversityFellowship, Infectious Disease, 1997 - 2000
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1994 - 1997
University of Michigan Medical SchoolClass of 1994

Certifications & Licensure

CA State Medical License 2013 - 2025
MD State Medical License 1997 - 2013
OH State Medical License 1996 - 1998

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Publications & Presentations

PubMed

Sex differences and immune correlates of Long Covid development, symptom persistence, and resolution.
Rebecca E Hamlin, Shaun M Pienkos, Leslie Chan, Mikayla A Stabile, Kassandra Pinedo
Science Translational Medicine. 2024-11-13
Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda.
Jessica Ferguson Toll, Elsa Solà, Maria Alejandra Perez, Salvatore Piano, Alice Cheng
Hepatology Communications. 2024-10-01
10 citations
Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial.
Linda N Geng, Hector Bonilla, Haley Hedlin, Karen B Jacobson, Lu Tian
JAMA Internal Medicine. 2024-09-01

Journal Articles

Impact of Pre-Transplant Donor BK Viruria in Kidney Transplant Recipients
Aruna K Subramanian, Amy E Gallo, Jane C Tan, Gregory A Storch, Jason Kurzer, Benjamin A Pinsky, Waldo Concepcion, Susanna K Tan, Diane Alonso, The Journal of Infectious Diseases

Other

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Aruna Subramanian, MD, The New England Journal of Medicine
https://www.doximity.com/articles/5d801831-c3b0-4ab4-9bf0-19bd673040b5
UpToDate, Wolters Kluwer Health - 2011-06-15

Authored Content

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19May 2020
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19May 2020

Press Mentions

What Does COVID-19 Do to Your Brain?February 7th, 2022
Antibodies in Blood Soon After COVID-19 Onset May Predict SeverityJanuary 18th, 2022
Promising COVID Treatments Could Reach San Francisco Pharmacies by JanuaryDecember 3rd, 2021
Join now to see all